Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Please find enclosed a Press Release on

"Dr. Reddy's announces the first-to-market launch of over-the-counter, store-brand equivalent of Allegra-D

24 HR in the U.S. Market"

This is for your information.

For Dr. Reddy's Laboratories Limited

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Dr. Reddy's announces the first-to-market

launch of over-the-counter,

store-brand equivalent of Allegra-D

24 HR in the U.S. Market

Hyderabad, India and Princeton, NJ,

USA. July 22, 2022 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along

with its subsidiaries together referred to as "Dr. Reddy's") today announced the first-to-market launch of over-the-counter

(OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D

24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

"The launch of Dr. Reddy's

Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, is an important addition to our upper respiratory

portfolio of OTC products," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories. "This first-to-market

launch is a testament to our deep capabilities and our continued efforts to bring high quality, affordable store-brand alternatives

for our customers and patients."

Dr. Reddy's OTC Fexofenadine HCl

180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP is an over-the-counter oral antihistamine and nasal decongestant

for the temporary relief of nasal and sinus congestion due to colds or allergies. It temporarily relieves sneezing; runny nose;

itchy, watery eyes; and itchy nose or throat due to allergies.

Allegra-D 24 HR had U.S. retail sales

of approximately $45 million as of May 2022 according to IRI*.

Dr. Reddy's OTC Fexofenadine HCl

180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP will be available in 5-count, 10-count, and 15-count pack sizes.

Allegra-D is a registered trademark

*IRI POS TOTAL US - Multi-Outlet

(MULO) period ending May 15, 2022

Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated

pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers

a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated

formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management

and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia

& CIS countries, and Europe. For more information, log on to: www.drreddys.com

This press release may include statements of future expectations and other forward-looking statements that are based on the management's

current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance

or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking

by reason of context, the words "may", "will", "should", "expects", "plans",

"intends", "anticipates", "believes", "estimates", "predicts", "potential",

or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may

differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance

of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of

insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive

factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions

or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed

by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics

or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public

filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking

Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation

to update any information contained herein.